Pajjiż: New Zealand
Lingwa: Ingliż
Sors: Medsafe (Medicines Safety Authority)
Nicotine 10 mg/mL;
Johnson & Johnson (New Zealand) Limited
Nicotine 10 mg/mL
10 mg/mL
Nasal spray solution
Active: Nicotine 10 mg/mL Excipient: Citric acid Dibasic sodium phosphate dodecahydrate Disodium edetate dihydrate Methyl hydroxybenzoate Monobasic sodium phosphate dihydrate NNS Aroma DZ-03226 Polysorbate 80 Propyl hydroxybenzoate Purified water Sodium chloride
Bottle, glass, 1x10ml, 10 mL
Prescription
Prescription
Siegfried Ltd
Package - Contents - Shelf Life: Bottle, glass, 1x10ml - 10 mL - 24 months from date of manufacture stored at or below 25°C
1993-03-30
Medsafe Logo INFORMATION FOR CONSUMERS Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search Consumer Medicine Information NICORETTE ® Nasal Spray Nicotine 10 mg/mL nasal spray What is in this leaflet This leaflet answers some common questions about Nicorette Nasal Spray. It does not contain all the available information or take the place of professional advice such as talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using Nicorette Nasal Spray against the benefits it is expected to have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What Nicorette Nasal Spray is used for Nicorette Nasal Spray helps you to give up smoking by relieving the desire to smoke, as well as some of the unpleasant effects, which smokers experience when they stop smoking. How Nicorette Nasal Spray works Smokers have both a physical reliance on nicotine (i.e. the body becomes dependent on nicotine) and a psychological reliance on the smoking habit itself. When you give up smoking, your body will miss the effects of nicotine and you will miss the habit of smoking. Nicorette Nasal Spray helps you to tackle these two sides of the problem separately, instead of all at once. It is your body's dependence on nicotine, which causes withdrawal symptoms when you suddenly stop smoking. Nicotine is an addictive substance. Symptoms may include irritability, restlessness, depression, weight gain, and craving for cigarettes. weight gain, and craving for cigarettes. Nicorette Nasal Spray is intended to ease such withdrawal symptoms by providing your body with nicotine. This Aqra d-dokument sħiħ
DATA SHEET NICORETTE ® NASAL SPRAY _10MG/ML _ PRESENTATION NICORETTE Nasal Spray containing 10mg/ml nicotine is a clear to weakly opalescent, colourless to light yellow solution filled in a brown glass container with a spray pump delivering 50 microL per spray. USES _ACTIONS _ NICORETTE Nasal Spray is a treatment aid to smoking cessation. Clinical studies have shown that the nicotine replacement from nicotine containing products can help people give up smoking. Nicotine is an agonist of nicotinic receptors in the peripheral and central nervous systems. In man as in animals nicotine had been shown to produce both behavioural stimulation and depression. The administration of NICORETTE Nasal Spray eliminates the other ingredients contained in tobacco smoke such as tar, carbon monoxide and irritating gases. _PHARMACOKINETICS _ Following administration of one dose NICORETTE Nasal Spray approximately 56% of the nicotine enters the systemic circulation. The volume of distribution following iv administration of nicotine is approximately (2 to) 3 L/kg and the half life ranges from 1-2 hours. The major eliminating organ is the liver, and average plasma clearance is about 1.2 L/min; the kidney and lung also metabolise nicotine. More than 20 metabolites of nicotine have been identified, all of which are believed to be less active than nicotine. The primary metabolite of nicotine in plasma, cotinine, has a half life of 15-20 hours and concentrations exceed nicotine by 10-fold. Plasma protein binding of nicotine is <5%. Therefore changes in nicotine binding from the use of concomitant medicines or alterations of plasma proteins by disease states would not be expected to have a significant effect on nicotine kinetics. The primary urinary metabolites are cotinine (15% of the dose) and trans-3- hydroxycotinine (45% of the dose). Usu Aqra d-dokument sħiħ